Inventiva S.A. (IVA)
Inventiva is a French biopharmaceutical company developing lanifibranor, an oral treatment for the liver disease MASH. It last closed at $3.22 on Nov 17, down 3.01% on the day. IVA last reported earnings on Fri, Sep 25, 2026. The average 12-month price target from 4 analysts is $16.75 (+420.2% from the last close), with a high of $21.00 and a low of $14.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $400K, the largest $400K.
Key Stats
Last 12 monthsNot reported for this period.
From IVA's SEC filings, latest 20-F for the period ending Jun 30, 2025 (filed Apr 8). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on IVA in the past 90 days. The average target is $16.75, with a high of $21.00 and a low of $14.00, compared with the last close of $3.22.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 5 | HC Wainwright & Co. | Maintained | Buy | $14 |
| Oct 2 | Truist Securities | Maintained | Buy | $18 |
| Sep 29 | Canaccord Genuity | Maintained | Buy | $21 |
| Sep 15 | Guggenheim | Maintained | Buy | $14 |
| Aug 16 | HC Wainwright & Co. | Maintained | Buy | $13 |
Technical Analysis
The stock is 15% below its 20 day and 11% below its 50 day average. It is 46% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38). The nearest support is the Pivot S1 at $3.11, and the nearest resistance the Pivot R1 at $3.34.
| RSI (14) | 38.38 | Weak, oversold below 30 | Neutral |
| MACD | 0.00 | Below its signal line | Bearish |
| Stochastic | 9.8 | Near the bottom of its range | Oversold |
| ADX (14) | 27.1 | Trending down | |
| Williams %R | -90.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -251.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −20.1% | Change over 10 sessions | Bearish |
| ATR (14) | $0.28 | Typical daily range, 8.6% of price |
| RSI (14) | 39.20 | Weak, oversold below 30 | Neutral |
| MACD | -0.35 | Below its signal line | Bearish |
| Stochastic | 32.8 | Middle of its range | Neutral |
| ADX (14) | 15.6 | No clear trend | |
| Williams %R | -82.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -86.0 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −19.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.58 | Typical daily range, 18.1% of price |
What happened before
See how IVA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How IVA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in IVA in the last 90 days.
Dark Pool
30DIVA Institutional Ownership
Full report →- ▲52 buying vs 39 selling
- ▲Shares held by funds +7.9%
- ▲Funds holding +10
- ▼Superinvestors: 1 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 98 | 88 | +11.4% |
| In funds' top 10 | 4 | 4 | 0.0% |
| Held by funds | – | – | – |
| New / increased | 25 / 27 | 31 / 36 | −22.4% |
| Reduced / sold out | 24 / 15 | 7 / 7 | +178.6% |
| Put/call ratio | 0.00 | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IVA is in one of them and how their past IVA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IVA in an article yet. Here's the latest on the wider market.
About Inventiva S.A.
Inventiva is a biopharmaceutical company based in Daix, France. It focuses on developing treatments for MASH, a progressive chronic liver disease marked by fat buildup, inflammation and scarring in the liver. Its main candidate, lanifibranor, is an orally available small molecule that is being studied in patients with MASH. The company aims to offer the treatment to these patients if regulators approve it.
- Headquarters
- Daix, France


